

## **Product** Data Sheet

## RANK L/TNFSF11 Protein, Human (HEK293, mFc)

Cat. No.: HY-P73682

Tumor necrosis factor ligand superfamily member 11; ODF; RANKL; CD254; TNFSF11 Synonyms:

Species: HEK293 Source:

Accession: O14788-2 (G63-D244)

Gene ID: 8600 Molecular Weight: 50-60 kDa

Ρ					

1 KOI EKIIES				
Biological Activity	<ol> <li>The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells and the ED<sub>50</sub> is 16 ng/mL.</li> <li>Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF11B His at 2 μg/mL (100 μl/well) can bind Human RANKL mFc, the EC<sub>50</sub> of Human RANKL mFc is 15-80 ng/mL.</li> </ol>			
Appearance	Lyophilized powder.			
Formulation	Lyophilized from a 0.2 $\mu$ m filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.			
Endotoxin Level	<1 EU/μg, determined by LAL method.			
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 $\mu g/mL$ in ddH <sub>2</sub> O.			
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.			
Shipping	Room temperature in continental US; may vary elsewhere.			

## **DESCRIPTION**

Background

RANKL (TNFSF11) belongs to TNF family. RANKL is a type II transmembrane protein and is a receptor activator of NF-кВ (RANK) ligand. RANKL is an activator of RANK. RANKL binds to RANK and induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. In bone tissue, RANKL is expressed by osteoblasts, osteocytes and immune cells, especially in osteoblasts and osteocytes[1]. RANKL is also expressed by T cells and increases proliferation and survival of dendritic cells<sup>[2]</sup>. Human RANKL shares 82.02% and 84.44% common aa identity with mouse and rat respectively. Human RANKL consists of

cytoplasmic domain (1-47), helical domain (48-68), and extracellular domain (69-317). The soluble chain (140-317) is released when cleaved by enzymes such as matrix metalloproteinases (MMP3 or 7) and ADAM<sup>[1][3]</sup>.

RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs)[1].

## **REFERENCES**

- [1]. Ono T, et al. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020 Feb 7;40:2.
- [2]. Li B, et al. Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis. Front Immunol. 2022 Mar 21;13:824117.
- [3]. Tobeiha M, et al. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. Biomed Res Int. 2020 Feb 19;2020:6910312.
- [4]. Mikami S, et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol. 2009 Aug;218(4):530-9.
- [5]. Peng X, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One. 2013;8(3):e58361.
- [6]. Lloyd SA, et al. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif Tissue Int. 2008 May;82(5):361-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA